Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.
Gilead Sciences agreed to acquire Tubulis GmbH for upwards of $5 billion in a deal that significantly expands Gilead's oncology pipeline and establishes Munich as a dedicated antibody-drug conjugates (ADC) research hub within the company.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
Gilead is set to pay $3.15 billion in upfront cash consideration, with up to $1.85 billion in additional contingent milestone payments.1 The transaction is expected to close in the second quarter of 2026 and will be financed through a combination of cash on hand and senior unsecured notes.
Following closing, Tubulis will operate as a dedicated ADC research organization within Gilead, with its Munich site serving as a center for ADC innovation.1
The acquisition builds on an existing
“The agreement to acquire Tubulis is a significant milestone in Gilead’s progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline,” said Daniel O’Day, chairman and chief executive officer, Gilead Sciences.
The deal adds two clinical-stage ADC assets and a next-generation conjugation platform. TUB-040 is a NaPi2b-directed topoisomerase-I inhibitor ADC currently in Phase Ib/II development for platinum-resistant ovarian cancer and non-small cell lung cancer, two indications with significant unmet need and limited effective treatment options after initial therapy fails.2 TUB-030 targets the 5T4 antigen and has shown promising early clinical data across multiple solid tumor types.
Beyond the individual assets, Tubulis' conjugation technology platforms are designed to more selectively deliver diverse payloads to tumor cells, potentially improving the therapeutic window of ADC therapy—a modality that has seen significant industry investment but remains limited by off-target toxicity challenges in existing approaches.
ADCs have emerged as one of the most competitive and rapidly evolving areas of oncology drug development, with multiple approved products already transforming treatment in breast cancer, bladder cancer, and other solid tumors.
The Tubulis acquisition adds differentiated next-generation ADC capabilities to a pipeline Daniel O'Day, Gilead's chairman and CEO, described as already the strongest and most diverse in the company's history.
“Today’s agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities. Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company’s history,” said O’Day.
Dominik Schumacher, CEO and co-founder of Tubulis, said joining Gilead provides the scientific expertise, global development infrastructure, and scale needed to translate the company's platform into medicines for patients, capabilities that would have taken years for an independent company to build.
“Joining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide. Through our existing collaboration, Gilead has already seen the potential of our technologies and together, we are well positioned to accelerate the development of our ADC pipeline. I’m deeply grateful to the Tubulis team, our Board of Directors, investors, and partners for their commitment and helping make this milestone possible,” said Schumacher.
The deal is Gilead's second significant oncology acquisition in recent weeks, following its agreement to
